Ocular Implants Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)

Ocular Implants Market Growth Drivers & Opportunities

Rising Incidence of Eye Disorders Drives Market

The biggest driver for the market is the rising incidence of disorders leading to partial or complete vision loss. The World Health Organization (WHO) estimates the global incidence of vision impairment at 2.2 billion people. They are not only a health concern but also a source of economic burden, with annual costs of over USD 440 billion in lost productivity due to vision loss. Additionally, around 19 million children below the age of 15 have impaired vision. The WHO lists macular degeneration, cataracts, refractive errors, glaucoma, and diabetic retinopathy as the prime causes of vision loss. The global incidence of these diseases as per the WHO is as follows: refractive error (88.4 million), cataract (94 million), AMD (8 million), diabetic retinopathy (3.9 million), and glaucoma (7.7 million).

Technological Advancements in Eye Care Offer Several Opportunities

Ocular diagnostic technology advancements have resulted in increased product uptake. These new technologies are helping enhance results for eye surgeries and open up new ways of seeing for persons who are blind. Thus, the growing acceptance of innovative ocular equipment, such as artificial or bionic eyes and glaucoma devices, has created several opportunities for industry players.

Tough Regulatory Scenario Impedes Market Growth

The biggest restraint for the ocular implants market is the stringent regulations for patient safety and product effectiveness around the world. The U.S. Food and Drug Administration (FDA) and European Medicine Agency (EMA) have some of the most-stringent such regulations, with developing countries also modifying theirs on similar lines. It can take up to 10 years for a health product to go from the discovery stage to marketing approval, consuming massive investments and resources in the process. Even after the approval, risks of adverse effects and subsequent product recalls persist. Additionally, newer implants can be expensive for people in developing countries and those without insurance coverage.

Ocular Implants Market Analysis

Product Insights

Glaucoma implants dominate the market with 40% share. This can be ascribed to the introduction of innovative glaucoma-implanted devices, such as micro-invasive glaucoma surgery (MIGS), and the initiatives of government and private organizations to raise glaucoma awareness. The World Glaucoma Association (WGA) organizes World Glaucoma Week each year to increase awareness about the risk and prevalence of glaucoma. Glaukos Corporation, as a sponsor, has developed a global education and awareness campaign and is cooperating with eye care institutions to provide free glaucoma screenings.

The intraocular lenses category will have the highest CAGR, of 5%, during 2024–2030 in the market. This is because of the extensive usage of intraocular lenses in the treatment of nearsightedness, farsightedness, and presbyopia. The overall number of patients receiving cataract surgery has more than tripled in a decade, which has also boosted the demand for these lenses. Furthermore, technological developments and increased awareness in developing countries are also expected to drive the market in this category.

These products are covered in the report:

• Intraocular Lenses (Fastest-Growing Category)
• Glaucoma Implants (Largest Category)
• Corneal Implants
• Others

Application Insights

Glaucoma is the largest category in the market, with 40% share. This is attributed to the increasing number of people with this disease and their rising awareness of it. As per the American Academy of Ophthalmology, 111.8 million people around the world will have this eye condition by 2040. Several agencies globally are working to raise awareness of this disease, which can cause blindness by damaging the optical nerve.

The AMD category is expected to witness the highest CAGR during the forecast period. The biggest reason for it is the growing geriatric population as it is highly susceptible to this disease. As per studies, compared to 196 million in 2021, 288 million people worldwide will have this condition by 2040. Further, according to Johns Hopkins Medicine, the most-common cause of loss of vision among people aged 50 and more is AMD. With the WHO forecasting the global population of people in the age group of 65 and above to grow by 400 million between 2020 and 2050, the demand for AMD treatment will continues to rise.

We have analyzed the following applications:

• Cataract
• Glaucoma (Largest Category)
• Age-Related Macular Degeneration (Fastest-Growing Category)
• Others

End User Insights

Hospitals are the largest end users with 55% share in 2024. This is because hospitals are large healthcare organizations that provide a variety of specialist treatments under one roof, and they have skilled ocular practitioners and witnessed increased patient footfall.

Ambulatory surgery centers are expected to witness the highest CAGR, of 7%, over this decade. This is because of the increasingly commonness of glaucoma and cataracts, which raises the footfall at hospitals. The lengthening waiting times compels many people to visit ASCs, which also offer cost-effective treatments. Further, cataract surgeries are not as technically demanding, which is why they can be performed on an outpatient basis.

The report contains analysis on the below-mentioned end users:

• Hospitals (Largest Category)
• Ambulatory Surgery Centers (Fastest-Growing Category)
• Specialty Eye Institutes
• Others

Material Insights

The non-biodegradable bifurcation dominates the market with a share of 70%. This is because non-biodegradable ocular implants were invented before biodegradable ones, and they have proved reliable and strong enough to last a long time. The materials most commonly used to make ocular implants are silicone, acrylic, polymethyl methacrylate, aluminum oxide, and even titanium.

The biodegradable bifurcation is the faster-growing category throughout the forecast period. This is attributed to the side-effects of synthetic ocular implants and the extensive R&D underway to develop materials that are more compatible with the body. Moreover, synthetic implants can have side-effects and complications. As per the U.S. Food and Drug Administration (FDA), they can include vision loss, need for additional ophthalmic surgeries, less effectiveness of the initial procedure, cloudiness in the cornea, cataracts, detached retina, bleeding, infection, or inflammation. Therefore, biodegradable implants are being developed as they have a lower chance of such complications since they are made form materials that mimic those the body is made of.

The segment is bifurcated as below:

• Biodegradable (Faster-Growing Category)
• Non-Biodegradable (Larger Category)

Regional Analysis

Moreover, the North American market will generate the highest revenue in 2024, of USD 6.5 billion. This is due to the presence of key players and an increase in the number of eye procedures in the region. Moreover, regional companies are concentrating their efforts on both developing and developed regions, in order to take advantage of all unexplored prospects.

The U.S. leads the North American market. Key players in the country are focusing on product approvals and launches of advanced ocular implants. For example, Alcon, a global leader in eye care, introduced the Clareon family of intraocular lenses (IOLs) in the U.S. in March 2022. Clareon uses Alcon's most modern IOL material to provide consistent visual outcomes and long-lasting clarity.

The APAC ocular implants market is projected to register the highest CAGR, of 8% during 2024–2030. There is a large pool of old population in APAC countries who are sensitive to chronic diseases like diabetes and are at a high risk of acquiring severe eye ailments. Also, vision loss can occur as a result of ocular illnesses. Moreover, due to the increase in healthcare infrastructure, surge in acceptance of technologically advanced products, and favorable patient demographics, the demand for ocular implants is rising rapidly in the region.

Below is the regional breakdown of the market:

• North America (Largest Regional Market)
  • U.S. (Larger Country Market)
  • Canada (Faster-Growing Country Market)
• Europe
  • Germany (Largest Country Market)
  • U.K.
  • France (Fastest-Growing Country Market)
  • Italy
  • Spain
• Asia-Pacific (APAC) (Fastest-Growing Regional Market)
  • Japan
  • China (Largest Country Market)
  • India (Faster-Growing Country Market)
  • South Korea
  • Australia
  • Rest of APAC
• Latin America (LATAM)
  • Brazil (Largest Country Market)
  • Mexico
  • Argentina (Faster-Growing Country Market)
  • Rest of LATAM
• Middle East and Africa (MEA)
  • Saudi Arabia (Faster-Growing Country Market)
  • South Africa (Largest Country Market)
  • U.A.E.
  • Rest of MEA

Ocular Implants Market Share

To ocular implants market is consolidated, primarily because these products are designed for direct human body contact; therefore, they must meet stringent patient safety regulations. This demands extensive expertise and investments in R&D, production, and clinical trials, making it difficult for new and smaller companies to operate in this field. Further, the established players have a long-standing brand reputation, with proper hospitals and experienced doctors more likely to recommend their products over those made by a company with a unproven track record in this field.

Ocular Implants Market News

• In July 2024, Alcon Vision LLC completed the acquisition of BELKIN Vision, thus adding the latter’s Direct Selective Laser Trabeculoplasty (DSLT) technology to its portfolio. The USD 81-million deal included UDS 65 million in cash and future options for payments worth USD 351 million.
• In May 2024, Bausch + Lomb Corporation announced the approval of Health Canada for its enVista Envy intraocular lens, which enables the full visual range.
• In April 2024, Carl Zeiss AG acquired Dutch Ophthalmic Research Center from Eurazeo SE.
• In February 2023, HOYA Corporation renewed its partnership with Orbis International to make eye care more accessible for children in India.